Time to Deterioration of Patient-reported Outcome Endpoints in Cancer Clinical Trials: Targeted Literature Review and Best Practice Recommendations

Overview

Journal J Patient Rep Outcomes

Specialty Health Services

Date 2024 Dec 18

PMID 39694990

Authors

Kim Cocks

Bellinda L King-Kallimanis

Joel Sims

Gill Worthy

Julia Stein

Lara Ayala-Nunes

Monika Achra

Zhanglin Lin Cui

Nalin Payakachat

Affiliations

Soon will be listed here.

Abstract

Background: Time to deterioration (TTD) endpoints are often utilized in the analysis of patient-reported outcome (PRO) data in oncology clinical trials but different endpoint definitions and analysis frameworks exist that can impact result interpretation. This review examined the analysis, reporting and heterogeneity of TTD endpoints in the literature, the impact of analysis methods on results, and provides recommendations for future trials.

Methods: A targeted literature review of articles published between 2017 and 2022 was performed to collate TTD endpoints reported in oncology randomized controlled trials (RCTs). Details of endpoints and results were extracted including; deterioration definition, PRO assessment schedule, methods for handling intercurrent events, statistical analysis methods, main trial results (overall survival and/or progression-free survival) and TTD endpoint results.

Results: Seventy RCTs were included covering 849 individual TTD endpoints. There were 17 primary cancer types, with lung (26%), breast (11%), and prostate (7%) cancers the most common. Most trials (71%) were for people with advanced cancer. Full definitions of TTD endpoints were often missing. There were no clear trends for a specific TTD definition within cancer types or stages. However, statistical analysis methods were consistent among trials.

Conclusion: The TTD definition can vary and is ultimately driven by the research question. Points to consider for successfully implementing PRO TTD endpoints in oncology include consideration of the trial setting (e.g., early vs. advanced cancer), expected treatment effect (e.g., improvement vs. worsening), likely adverse event profile (including early vs. delayed) and PRO data collection frequency in order to improve utility of these endpoints.

References

Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M . Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018; 36(25):2578-2584. PMC: 6366953. DOI: 10.1200/JCO.2018.78.5865. View

Yamaguchi K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T . Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial. Clin Drug Investig. 2020; 41(1):53-64. PMC: 7815617. DOI: 10.1007/s40261-020-00979-3. View

Leighl N, Karaseva N, Nakagawa K, Cho B, Gray J, Hovey T . Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. Eur J Cancer. 2019; 125:49-57. DOI: 10.1016/j.ejca.2019.11.006. View

Campelo M, Lin H, Zhu Y, Perol M, Jahanzeb M, Popat S . Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L). Lung Cancer. 2021; 155:68-77. DOI: 10.1016/j.lungcan.2021.03.005. View

Fiteni F, Pam A, Anota A, Vernerey D, Paget-Bailly S, Westeel V . Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology. Expert Rev Anticancer Ther. 2015; 15(8):885-91. DOI: 10.1586/14737140.2015.1047768. View

Moy B, Oliveira M, Saura C, Gradishar W, Kim S, Brufsky A . Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens. Breast Cancer Res Treat. 2021; 188(2):449-458. PMC: 8260518. DOI: 10.1007/s10549-021-06217-4. View

Garon E, Cho B, Reinmuth N, Lee K, Luft A, Ahn M . Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). Clin Lung Cancer. 2021; 22(4):301-312.e8. DOI: 10.1016/j.cllc.2021.02.010. View

Bedke J, Rini B, Plimack E, Stus V, Gafanov R, Waddell T . Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. Eur Urol. 2022; 82(4):427-439. DOI: 10.1016/j.eururo.2022.06.009. View

Goldman J, Garassino M, Chen Y, Ozguroglu M, Dvorkin M, Trukhin D . Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer. 2020; 149:46-52. DOI: 10.1016/j.lungcan.2020.09.003. View

10.

Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P . Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?. Qual Life Res. 2013; 24(1):5-18. PMC: 4282717. DOI: 10.1007/s11136-013-0583-6. View

11.

Porcu P, Hudgens S, Horwitz S, Quaglino P, Cowan R, Geskin L . Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2020; 21(2):97-105. PMC: 7878351. DOI: 10.1016/j.clml.2020.09.003. View

12.

Yoh K, Atagi S, Reck M, Garon E, Aix S, Moro-Sibilot D . Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated -mutated metastatic non-small-cell lung cancer. Curr Med Res Opin. 2020; 36(10):1667-1675. DOI: 10.1080/03007995.2020.1808781. View

13.

Meregaglia M, Malandrini F, Angelini S, Ciani O . The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022. Appl Health Econ Health Policy. 2023; 21(6):925-935. PMC: 10627987. DOI: 10.1007/s40258-023-00827-3. View

14.

Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T . Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021; 6(8):649-658. DOI: 10.1016/S2468-1253(21)00110-2. View

15.

Lawrance R, Degtyarev E, Griffiths P, Trask P, Lau H, DAlessio D . What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?. J Patient Rep Outcomes. 2020; 4(1):68. PMC: 7445213. DOI: 10.1186/s41687-020-00218-5. View

16.

Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M . Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2018; 19(5):441-449.e4. DOI: 10.1016/j.cllc.2018.05.011. View

17.

Motzer R, Porta C, Alekseev B, Rha S, Choueiri T, Mendez-Vidal M . Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol. 2022; 23(6):768-780. PMC: 10284118. DOI: 10.1016/S1470-2045(22)00212-1. View

18.

Bascoul-Mollevi C, Barbieri A, Bourgier C, Conroy T, Chauffert B, Hebbar M . Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results. Qual Life Res. 2020; 30(1):91-103. DOI: 10.1007/s11136-020-02605-3. View

19.

Li J, Cheng Y, Bai C, Xu J, Shen L, Li J . Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and.... Eur J Cancer. 2022; 169:1-9. DOI: 10.1016/j.ejca.2022.03.027. View

20.

Kaufman P, Toi M, Neven P, Sohn J, Grischke E, Andre V . Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. Oncologist. 2020; 25(2):e243-e251. PMC: 7011625. DOI: 10.1634/theoncologist.2019-0551. View